CAR-T Cell Expansion — hPL vs FBS

The shift from FBS to human platelet lysate (hPL) in CAR-T cell manufacturing is no longer a regulatory preference — it is becoming the de facto standard for clinical-grade production. But the decision is not purely regulatory. There is a growing body of published data showing that hPL-expanded T cells are functionally different from FBS-expanded T cells in ways that matter for therapeutic efficacy. This post reviews what the data shows.

Why the serum source matters for T cell biology

T cells are exquisitely sensitive to the cytokine and growth factor environment during ex vivo expansion. The serum supplement is not merely a nutrient source — it is a complex biological signal that shapes T cell phenotype, exhaustion status, memory differentiation, and ultimately in vivo persistence after infusion. Two serum sources that look similar on a CoA can produce T cells with fundamentally different functional profiles.

FBS provides bovine growth factors — IGF-1, TGF-β, PDGF, EGF — that are not species-matched for human T cell receptors. Human platelet lysate provides human-sequence equivalents of these factors, released from platelet alpha granules during freeze-thaw lysis. For human T cells, species-matched growth factors are more potent at lower concentrations — meaning hPL at 5% can drive faster expansion than FBS at 10%.

The published data — expansion rate

Multiple published studies have compared FBS and hPL for primary human T cell and CAR-T expansion. The consistent finding:

The higher expansion rate in hPL is primarily driven by higher concentrations of human PDGF-AB/BB and EGF released from platelet alpha granules — both of which signal through receptors expressed on activated T cells and drive proliferation more effectively than their bovine equivalents in FBS.

The critical difference — T cell phenotype and exhaustion

Expansion rate alone is not the relevant metric for CAR-T manufacturing. What matters is the phenotype of the expanded cells — specifically the memory differentiation status and exhaustion marker expression, which directly predict in vivo persistence and therapeutic efficacy after infusion.

T cell memory differentiation follows a hierarchy: naïve (Tnaive) → stem cell memory (Tscm) → central memory (Tcm) → effector memory (Tem) → terminally differentiated effector (Teff). Less differentiated cells (Tscm, Tcm) persist longer in vivo and are associated with superior clinical responses in CAR-T therapy. More differentiated cells (Tem, Teff) expand rapidly in vitro but exhaust quickly after infusion.

CAR-T specific considerations

For CAR-T cells specifically (as opposed to polyclonal T cell therapies), the serum source affects not only the non-transduced T cell expansion but also the transduction efficiency of the lentiviral or retroviral vector used to introduce the CAR construct:

• Lentiviral transduction efficiency: hPL-expanded T cells show comparable or higher lentiviral transduction efficiency compared to FBS-expanded cells — despite faster proliferation (which can dilute the integrated provirus). The higher viability of hPL-expanded cells at the time of transduction may account for this
• CAR expression stability: CAR expression levels (measured by CAR surface density and MFI) are comparable between FBS and hPL conditions post-transduction
• Cytotoxic function: hPL-expanded CAR-T cells show equivalent or superior target cell killing in co-culture assays, consistent with lower exhaustion marker expression

Regulatory considerations — why hPL is increasingly mandatory

EMA Advanced Therapy Guidelines (EMA/CAT/CPWP/573420/2023) strongly encourage elimination of xenogenic (animal-derived) components from ATMP manufacturing processes. FBS introduces:

• TSE/BSE risk requiring country-of-origin certification and lot-specific documentation
• Adventitious agent risk (BVDV, other bovine viruses) requiring testing per lot
• Potential bovine protein immunogenicity in the final cell product (residual FBS proteins adsorbed to T cell surfaces)
• Lot-to-lot variability that complicates process consistency demonstration in the IND/CTA

Human platelet lysate, collected from screened human donors with IRB clearance and full documentation, eliminates all bovine-specific risks and simplifies the ATMP raw material risk assessment significantly.

Practical implementation — switching from FBS to hPL

The transition from FBS to hPL for T cell expansion is straightforward but requires attention to two specific issues:

1. Fibrinogen: hPL contains fibrinogen at 2–4 mg/mL — at body temperature in T cell culture medium, fibrinogen can form a gel that interferes with T cell suspension culture. Add heparin at 2 IU/mL to prevent fibrin gel formation. Alternatively, use fibrinogen-depleted hPL formulations.

2. Concentration: hPL at 5% is typically sufficient — higher concentrations (7.5–10%) may be used in the first 48–72 hours post-activation but are usually not needed throughout the expansion. The higher growth factor density in hPL means that 5% hPL typically outperforms 10% FBS, making it cost-neutral despite the higher per-mL price of hPL.